DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a comprehensive set of 2,320 bioactive compounds approved by leading regulatory bodies for clinical use, provided by APExBIO (product page). Every compound is QC-verified and pre-dissolved at 10 mM in DMSO for high-throughput or high-content screening workflows. The library is designed for drug repositioning and pharmacological target identification in disease models, including oncology and neurodegeneration (Cytochrome-C-Fragment-93-108.com). Mechanistic screens using the library have enabled identification of novel modulators such as sulfasalazine for sarcopenia (IC50 = 24 μM) (DOI:10.1016/j.exger.2025.112883). Format flexibility (96-well, deep-well, 2D barcoded tubes) and long-term stability (-20°C for 12 months, -80°C for 24 months) support diverse research pipelines.

Biological Rationale

Drug discovery increasingly leverages collections of clinically approved drugs to accelerate hypothesis testing and translational research (Mechanism-Driven Drug Discovery). The DiscoveryProbe™ FDA-approved Drug Library offers a unique resource of 2,320 compounds, each with a well-characterized mechanism of action, regulatory history, and clinical safety profile. These compounds include receptor agonists, antagonists, enzyme inhibitors, ion channel modulators, and pathway regulators. This breadth enables researchers to interrogate multiple biological pathways, facilitating drug repositioning and target validation in models of cancer, neurodegeneration, and metabolic disorders. Drug repurposing reduces development time and improves translational predictability by leveraging compounds with known human pharmacokinetics and toxicology profiles.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library embodies a broad mechanistic spectrum. Compounds are annotated for activity as:

• Receptor agonists/antagonists (e.g., beta-blockers, opioid antagonists).
• Enzyme inhibitors (e.g., kinase, protease, and topoisomerase inhibitors such as doxorubicin).
• Ion channel modulators (e.g., calcium and sodium channel blockers).
• Pathway regulators (e.g., mTOR, NF-κB, and insulin/IGF signaling modulators).

This diversity allows mechanism-driven screens, as demonstrated by the identification of sulfasalazine as a PHF20-YY1 pathway inhibitor in sarcopenia models (2025, DOI:10.1016/j.exger.2025.112883). Compounds are supplied as 10 mM DMSO solutions, ensuring solubility and compatibility with high-throughput platforms.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library enabled identification of sulfasalazine as a PHF20-YY1 inhibitor, reducing YY1 expression and enhancing muscle-specific gene expression in C2C12 myoblasts (IC50 = 24 μM) (DOI:10.1016/j.exger.2025.112883).
• In mouse models of muscle atrophy, sulfasalazine treatment led to enhanced muscle strength, function, and mitigation of muscle loss, supporting the repurposing approach (DOI:10.1016/j.exger.2025.112883).
• The library has been widely used for pharmacological target identification and drug repositioning in cancer, neurodegenerative, and infectious disease research (internal summary).
• Compounds are stable for 12 months at -20°C and up to 24 months at -80°C, with validated QC for each batch (APExBIO).
• High-throughput and high-content screening workflows are supported by standardized 96-well or deep-well plate formats, reducing liquid handling errors and improving reproducibility (internal summary).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• Drug repositioning screening in cancer, neurodegeneration, and metabolic disease models.
• Pharmacological target identification using phenotypic and mechanistic assays.
• High-throughput screening (HTS) and high-content screening (HCS) workflows.
• Mechanistic validation of pathway inhibitors, as shown in recent protein misfolding and muscle atrophy studies (internal reference).

This article extends prior analyses by providing explicit experimental benchmarks and workflow parameters from recent peer-reviewed studies, whereas earlier reviews (Cytochrome-C-Fragment-93-108.com) focused mainly on general use cases.

Common Pitfalls or Misconceptions

• Not all hits are immediately translatable: Some compounds may require additional validation in primary cells or animal models before clinical relevance is established.
• Off-target effects: Compounds approved for one indication may have off-target activities in unrelated pathways. Mechanistic follow-up is essential.
• Assay interference: DMSO-solubilized drugs or certain colored/fluorescent compounds can interfere with optical readouts in some high-content assays.
• Storage and handling: Failure to maintain recommended storage conditions (-20°C or -80°C) can compromise compound integrity.
• Library composition is fixed: Customization of the compound set is not supported in the standard L1021 kit; researchers with specialized needs should consult APExBIO for custom solutions.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied as pre-dissolved 10 mM DMSO solutions in 96-well or deep-well plates, or in 2D barcoded tubes, streamlining integration into automated screening platforms. Recommended storage is at -20°C for up to 12 months or at -80°C for up to 24 months. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice for larger batches. Compounds are compatible with standard liquid-handling robots and multi-well plate readers. Quality control includes LC-MS/MS and NMR verification. For detailed mechanistic screening strategies, see the recent synthesis on integrating high-throughput screening with translational pipelines (Mechanism-Driven Drug Discovery).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO provides a robust, reproducible, and translationally relevant platform for mechanism-driven screening, drug repositioning, and pharmacological target identification. Its standardized formats, comprehensive annotation, and regulatory provenance make it a cornerstone for modern high-throughput screening in oncology, neurodegenerative disease, and beyond. Future advances will likely integrate AI-driven hit prioritization and combinatorial screens, further leveraging the curated power of this resource for next-generation therapy discovery. For ordering and technical specifications, visit the product page.